Assenagon Asset Management S.A. Trims Stock Position in Omnicell, Inc. $OMCL

Key Points

• Assenagon Asset Management S.A. significantly reduced its stake in Omnicell, Inc. by 91.0% in Q2, leaving it with 9,933 shares valued at $292,000.
• Institutional investors dominate Omnicell's stock, holding 97.70% of shares, with notable increases from firms like UBS AM and GAMMA Investing LLC.
• Recent analyst reports show a mixture of ratings, with Wells Fargo raising its price target from $37.00 to $40.00 and an average target price of $46.71 for Omnicell's stock.

Assenagon Asset Management S.A. lessened its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 91.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,933 shares of the company's stock after selling 100,627 shares during the period. Assenagon Asset Management S.A.'s holdings in Omnicell were worth $292,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in OMCL. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Omnicell by 22.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company's stock worth $5,306,000 after purchasing an additional 21,847 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Omnicell by 2,892.5% during the first quarter. GAMMA Investing LLC now owns 43,211 shares of the company's stock valued at $1,511,000 after purchasing an additional 41,767 shares in the last quarter. Bridge City Capital LLC lifted its holdings in Omnicell by 1.6% during the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock valued at $1,403,000 after purchasing an additional 650 shares in the last quarter. Accurate Wealth Management LLC lifted its holdings in Omnicell by 27.4% during the first quarter. Accurate Wealth Management LLC now owns 36,131 shares of the company's stock valued at $1,263,000 after purchasing an additional 7,762 shares in the last quarter. Finally, Diversified Trust Co lifted its holdings in Omnicell by 2.3% during the first quarter. Diversified Trust Co now owns 22,660 shares of the company's stock valued at $792,000 after purchasing an additional 513 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares in the company, valued at approximately $3,679,212.25. This trade represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.52% of the company's stock.

Wall Street Analyst Weigh In

OMCL has been the topic of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Piper Sandler reduced their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $30.72 on Monday. The firm has a 50-day simple moving average of $31.30 and a 200-day simple moving average of $30.66. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of 61.44, a price-to-earnings-growth ratio of 6.71 and a beta of 0.82. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same period in the prior year, the business earned $0.51 earnings per share. The company's quarterly revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.